30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Artiva Biotherapeutics Inc (ARTV)

Track

Over the last 90 days, Artiva Biotherapeutics Inc. saw significant insider buying, primarily from RA CAPITAL MANAGEMENT, L.P., totaling over $108 million. This contrasts with a smaller volume of sales by executives, including the CEO and CMO, amounting to approximately $1 million. The stock has experienced a notable price increase of 61.4% in the same period.
Stock chart
Ticker: ARTV Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
RA CAPITAL MANAGEMENT, L.P.
1 purchase — total 100,000 USD
Buy 16 Jun 2026
Value US$3,123,947.88 | Price 377.46 | Shares 99,607
Buy 15 Jun 2026
Value US$4,460,507.53 | Price 24.10 | Shares 81,905
Buy 12 Jun 2026
Value US$100,000.00 | Price 8.57 | Shares 1,000
Buy 11 Jun 2026
Value US$100,000.00 | Price 7.91 | Shares 1,000
Buy 11 Jun 2026
Value US$100,000.00 | Price 7.91 | Shares 1,000
Buy 10 Jun 2026
Value US$100,000.00 | Price 7.00 | Shares 1,000
Buy 10 Jun 2026
Value US$100,000.00 | Price 7.00 | Shares 1,000
Buy 9 Jun 2026
Value US$100,000.00 | Price 6.91 | Shares 1,000
Sale 19 May 2026
Value US$63,072.62 | Price 9.01 | Shares 7,002
Sale 19 May 2026
Value US$244,252.79 | Price 9.01 | Shares 27,116
Sale 19 May 2026
Value US$63,386.48 | Price 9.01 | Shares 7,037
Sale 19 May 2026
Value US$79,178.56 | Price 9.01 | Shares 8,790
Sale 19 May 2026
Value US$27,879.14 | Price 9.01 | Shares 3,095
Proposed sale 18 May 2026
Value US$258,160.00 | Price 9.22 | Shares 28,000
Proposed sale 18 May 2026
Value US$64,540.00 | Price 9.22 | Shares 7,000
Proposed sale 18 May 2026
Value US$82,980.00 | Price 9.22 | Shares 9,000
Proposed sale 18 May 2026
Value US$32,270.00 | Price 9.22 | Shares 3,500
Proposed sale 18 May 2026
Value US$69,150.00 | Price 9.22 | Shares 7,500
Buy 11 May 2026
Value US$3,999,997.44 | Price 11.52 | Shares 347,222
Buy 11 May 2026
Value US$12,499,994.88 | Price 11.52 | Shares 1,085,069
Buy 11 May 2026
Value US$74,999,992.32 | Price 11.52 | Shares 6,510,416
Proposed sale 15 Dec 2025
Value US$42,071.70 | Price 3.30 | Shares 12,749
Planned sale 15 Dec 2025
Value US$19,122.00 | Price 6.00 | Shares 3,187
Proposed sale 17 Nov 2025
Value US$20,718.75 | Price 3.25 | Shares 6,375
Planned sale 17 Nov 2025
Value US$21,522.00 | Price 3.38 | Shares 6,375
Proposed sale 17 Oct 2025
Value US$70,635.00 | Price 2.77 | Shares 25,500
Planned sale 17 Oct 2025
Value US$153,000.00 | Price 6.00 | Shares 25,500
Planned sale 15 Aug 2025
Value US$69,579.30 | Price 2.73 | Shares 25,500
Proposed sale 15 Aug 2025
Value US$68,850.00 | Price 2.70 | Shares 25,500
Buy 22 Jul 2024
Value US$8,259,912.00 | Price 12.00 | Shares 688,326
Buy 22 Jul 2024
Value US$91,740,084.00 | Price 12.00 | Shares 7,645,007
Buy 22 Jul 2024
Value US$9,999,996.00 | Price 12.00 | Shares 833,333
Buy 22 Jul 2024
Value US$4,999,992.00 | Price 12.00 | Shares 416,666
Buy 22 Jul 2024
Value US$19,999,992.00 | Price 12.00 | Shares 1,666,666
Buy 22 Jul 2024
Value US$4,999,992.00 | Price 12.00 | Shares 416,666
Buy 22 Jul 2024
Value US$4,999,992.00 | Price 12.00 | Shares 416,666
Buy 22 Jul 2024
Value US$19,999,992.00 | Price 12.00 | Shares 1,666,666
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-16 2026-06-16 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
99,607 +12.6%
377.46
US$3,123,948 		99,607 +12.6% 377.46 US$3,123,948
2026-06-16 2026-06-15 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
81,905 +0.3%
24.10
US$4,460,508 		81,905 +0.3% 24.10 US$4,460,508
2026-06-16 2026-06-12 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
33,863 +49.2%
240.85
US$3,254,028 		33,863 +49.2% 240.85 US$3,254,028
2026-06-11 2026-06-11 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
1,000 +3.5%
7.91
US$100,000 		1,000 +3.5% 7.91 US$100,000
2026-06-11 2026-06-11 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
1,000 +3.5%
7.91
US$100,000 		1,000 +3.5% 7.91 US$100,000
2026-06-11 2026-06-10 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
1,000 +0.0%
7.00
US$100,000 		1,000 +0.0% 7.00 US$100,000
2026-06-11 2026-06-10 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
1,000 +0.0%
7.00
US$100,000 		1,000 +0.0% 7.00 US$100,000
2026-06-11 2026-06-09 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
1,000 +3.2%
6.91
US$100,000 		1,000 +3.2% 6.91 US$100,000
2026-05-19 2026-05-19 S Sale
Horan Christopher

Chief Tech Operations Officer

Officer
7,002 -2.3%
9.01
US$63,073 		7,002 -2.3% 9.01 US$63,073
2026-05-19 2026-05-19 S Sale
Aslan Fred

Chief Executive Officer

Executive Director
27,116 -1.7%
9.01
US$244,253 		27,116 -1.7% 9.01 US$244,253
2026-05-19 2026-05-19 S Sale
Banerjee Subhashis

Chief Medical Officer

Officer
7,037 -4.6%
9.01
US$63,386 		7,037 -4.6% 9.01 US$63,386
2026-05-19 2026-05-19 S Sale
Bush Jennifer

COO, CLO, Compliance Officer

Officer
8,790 -2.5%
9.01
US$79,179 		8,790 -2.5% 9.01 US$79,179
2026-05-19 2026-05-19 S Sale
Raymon Heather

SVP, Research and Development

Officer
3,095 -2.0%
9.01
US$27,879 		3,095 -2.0% 9.01 US$27,879
2026-05-18 2026-05-18 PrS Proposed sale
Fred Aslan, M.D.

Officer; Director

Executive Director
28,000
9.22
US$258,160 		28,000 9.22 US$258,160
2026-05-18 2026-05-18 PrS Proposed sale
Subhashis Banerjee

Officer; Director

Executive Director
7,000
9.22
US$64,540 		7,000 9.22 US$64,540
2026-05-18 2026-05-18 PrS Proposed sale
Jennifer Bush

Officer; Director

Executive Director
9,000
9.22
US$82,980 		9,000 9.22 US$82,980
2026-05-18 2026-05-18 PrS Proposed sale
Heather Raymon

Officer; Director

Executive Director
3,500
9.22
US$32,270 		3,500 9.22 US$32,270
2026-05-18 2026-05-18 PrS Proposed sale
Christopher P. Horan

Officer; Director

Executive Director
7,500
9.22
US$69,150 		7,500 9.22 US$69,150
2026-05-28 2026-05-11 B Purchase
0.9
GC Corp.
Large shareholder
347,222 +27.5%
11.52
US$3,999,997 		347,222 +27.5% 11.52 US$3,999,997
2026-05-28 2026-05-11 B Purchase
0.9
GC Corp.
Large shareholder
1,085,069 +32.8%
11.52
US$12,499,995 		1,085,069 +32.8% 11.52 US$12,499,995
2026-05-13 2026-05-11 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
6,510,416 +74.9%
11.52
US$74,999,992 		6,510,416 +74.9% 11.52 US$74,999,992
2025-12-15 2025-12-15 PrS Proposed sale
FRED ASLAN

Director; Officer

Executive Director
12,749
3.30
US$42,072 		12,749 3.30 US$42,072
2025-12-15 2025-12-15 PlS Planned sale
Aslan Fred

President and CEO

Executive Director
3,187 -0.3%
6.00
US$19,122 		3,187 -0.3% 6.00 US$19,122
2025-11-17 2025-11-17 PrS Proposed sale
FRED ASLAN

Director; Officer

Executive Director
6,375
3.25
US$20,719 		6,375 3.25 US$20,719
2025-11-17 2025-11-17 PlS Planned sale
Aslan Fred

President and CEO

Executive Director
6,375 -1.8%
3.38
US$21,522 		6,375 -1.8% 3.38 US$21,522
2025-10-17 2025-10-17 PrS Proposed sale
FRED ASLAN

Director; Officer

Executive Director
25,500
2.77
US$70,635 		25,500 2.77 US$70,635
2025-10-17 2025-10-17 PlS Planned sale
Aslan Fred

President and CEO

Executive Director
25,500 -6.7%
6.00
US$153,000 		25,500 -6.7% 6.00 US$153,000
2025-08-18 2025-08-15 PlS Planned sale
Aslan Fred

President and CEO

Executive Director
25,500 -6.2%
2.73
US$69,579 		25,500 -6.2% 2.73 US$69,579
2025-08-15 2025-08-15 PrS Proposed sale
FRED ASLAN

Director; Officer

Executive Director
25,500
2.70
US$68,850 		25,500 2.70 US$68,850
2024-07-24 2024-07-22 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
688,326 +497.0%
12.00
US$8,259,912 		688,326 +497.0% 12.00 US$8,259,912
2024-07-24 2024-07-22 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
7,645,007 +729.1%
12.00
US$91,740,084 		7,645,007 +729.1% 12.00 US$91,740,084
2024-07-24 2024-07-22 B Purchase
2.6
5AM Partners VI, LLC
Large shareholder
833,333 +239.0%
12.00
US$9,999,996 		833,333 +239.0% 12.00 US$9,999,996
2024-07-22 2024-07-22 B Purchase
0.9
GC Corp.
Large shareholder
416,666 +49.4%
12.00
US$4,999,992 		416,666 +49.4% 12.00 US$4,999,992
2024-07-22 2024-07-22 B Purchase
0.9
GC Corp.
Large shareholder
1,666,666 +101.6%
12.00
US$19,999,992 		1,666,666 +101.6% 12.00 US$19,999,992
2024-07-22 2024-07-22 B Purchase
2.9
venBio Global Strategic Fund III, L.P.
Large shareholder
416,666 +27.4%
12.00
US$4,999,992 		416,666 +27.4% 12.00 US$4,999,992
2024-07-22 2024-07-22 B Purchase
0.8
Huh Yong-Jun
Non-Executive Director
416,666 +49.4%
12.00
US$4,999,992 		416,666 +49.4% 12.00 US$4,999,992
2024-07-22 2024-07-22 B Purchase
0.8
Huh Yong-Jun
Non-Executive Director
1,666,666 +101.6%
12.00
US$19,999,992 		1,666,666 +101.6% 12.00 US$19,999,992
Explore more

More insider trading research around Artiva Biotherapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America